TABLE 2.
Provincial price variations of anticancer medicines.
| Non-targeted anticancer medicines | Price variation (2015) | Price variation (2022) | Changes in price variation | Non-targeted anticancer medicines | Price variation (2015) | Price variation (2022) | Changes in price variation | Targeted anticancer medicines | Price variation (2015) | Price variation (2022) | Changes in price variation |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Busulfan | 0 | 115·02 | 115·02 | Fluorouracil | 428·14 | 305·78 | −122·36 | Alimta | 336·39 | 277·24 | −59·15 |
| Cyclophosphamide | 17·17 | 8·68 | −8 · 49 | Gemcitabine | 460·02 | 220·01 | −240·01 | Gefitinib | 155·13 | 144·54 | −10·59 |
| Ifosfamide | 258·58 | 99·03 | −159·55 | Hydroxyurea | 2·77 | 3·64 | 0·87 | Icotinib | 32·94 | 24·25 | −8 · 69 |
| Daunorubicin | 49·08 | 5·97 | −43·11 | Mercaptopurine | 0·32 | 1·23 | 0·91 | Imatinib | 817·51 | 443·37 | −374·14 |
| Doxorubicin | 42·4 | 337·24 | 294·84 | Arsenous acid | 22·11 | 3·16 | −18·95 | Rituximab | 264·7 | 313·28 | 48·58 |
| Etoposide | 31·66 | 144·37 | 112·71 | Asparaginase | 29·4 | 20·21 | −9 · 19 | Trastuzumab | 191·59 | 15·53 | −176·06 |
| Homoharringtonine | 42·38 | 68·66 | 26·28 | Calcium folinate | 65·68 | 109·4 | 43·72 | ||||
| Taxol | 500·09 | 83·15 | −416·94 | Capecitabine | 212·83 | 115·2 | −97·63 | ||||
| Vincristine | 21·65 | 50·39 | 28·74 | Carboplatin | 24·23 | 28·67 | 4·44 | ||||
| Letrozole | 22·7 | 33·65 | 10·95 | Cisplatin | 34·16 | 2·92 | −31·24 | ||||
| Tamoxifen | 0·96 | 4·09 | 3·13 | Oxaliplatin | 200·2 | 115·31 | −84·89 | ||||
| Cytarabine | 16·56 | 5·63 | −10·93 |